APO-ACYCLOVIR TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

ACYCLOVIR

זמין מ:

APOTEX INC

קוד ATC:

J05AB01

INN (שם בינלאומי):

ACYCLOVIR

כמות:

200MG

טופס פרצבטיות:

TABLET

הרכב:

ACYCLOVIR 200MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

100/500

סוג מרשם:

Prescription

איזור תרפויטי:

NUCLEOSIDES AND NUCLEOTIDES

leaflet_short:

Active ingredient group (AIG) number: 0115506002; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

1997-08-21

מאפייני מוצר

_____________________________________________________________________________________
_APO-ACYCLOVIR Product Monograph _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
APO-ACYCLOVIR
ACYCLOVIR TABLETS
APOTEX STANDARD
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
APOTEX INC. DATE OF PREPARATION:
150 SIGNET DRIVE
April 10, 1997
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
August 31, 2021
Control No. 255331
_____________________________________________________________________________________
_APO-ACYCLOVIR Tablets Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................................
6
DRUG INTERACTIONS
..........................................................................................................................................
9
DOSAGE AND ADMINISTRATION
......................................................................................................................
9
OVERDOSAGE
......................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................